食管癌患者放疗联合替吉奥治疗期间急性骨髓抑制的发生率及危险因素分析
Analysis of incidence and risk factors of acute myelosuppression in patients with esophageal cancer during radiotherapy combined with Tegio administration
张月锋 1李太平 1卢峰 1王瑜 1王光明1
作者信息
- 1. 阜阳市肿瘤医院放射治疗三病区,阜阳 236000
- 折叠
摘要
目的 探讨食管癌患者放疗联合替吉奥治疗期间急性骨髓抑制的发生情况及其影响因素.方法 回顾性分析2019年1月至2024年1月于阜阳市肿瘤医院接受食管癌放疗联合替吉奥治疗的60例患者的临床资料.采用单因素分析筛选出可能与食管癌放疗联合替吉奥治疗期间急性骨髓抑制发生的相关因素,采用多因素Logistic回归分析确定食管癌放疗联合替吉奥治疗期间发生急性骨髓抑制的独立危险因素.结果 单因素分析结果显示,骨髓抑制组患者白细胞(WBC)≤3.0×109·L-1占比、血红蛋白(Hb)≤100 g·L-1占比、中性粒细胞≤2.0×109·L-1占比、血细胞比容≤37%占比高于非骨髓抑制组(P<0.05);多因素Logistic回归分析结果显示,WBC、Hb、中性粒细胞升高是患者放疗联合替吉奥治疗期间发生急性骨髓抑制的保护因素(P<0.05).结论 食管癌放疗联合替吉奥治疗期间急性骨髓抑制的发生率较高,且其发生与多种因素相关.临床应根据患者的个体情况和危险因素评估,合理选择治疗方案,及时监测血常规指标,预防和处理急性骨髓抑制及其并发症,提高患者的生活质量和治疗效果.
Abstract
Objective To investigate the incidence of acute myelosuppression and its influencing factors during radiotherapy combined with tegafur treatment in patients with esophageal cancer.Methods Clinical data of 60 patients with esophageal cancer who received radiotherapy combined with tegafur treatment in Fuyang Tumor Hospital from January 2019 to January 2024 were retrospectively analyzed.Univariate analysis was used to screen potential factors related to acute myelosuppression during the treatment,and multivariate Logistic regression analysis was conducted to determine the independent risk factors for acute myelosuppression.Results Univariate analysis showed that the proportions of white blood cell(WBC)count≤3.0×109·L-1,hemoglobin(Hb)≤100 g·L-1,neutrophils≤2.0×109·L-1,and hematocrit≤37%were higher in the myelosuppression group than in the non-myelosuppression group(P<0.05).Multivariate Logistic regression analysis indicated that increased levels of WBC,Hb,and neutrophils were protective factors against acute myelosuppression during the treatment(P<0.05).Conclusion There is a high incidence of acute myelosuppression during radiotherapy combined with tegafur treatment in esophageal cancer,which is associated with multiple factors.Clinically,individual patient conditions and risk factors should be assessed to choose appropriate treatment plans.Routine blood parameters should be monitored promptly to prevent and manage acute myelosuppression and its complications,thereby improving the quality of life and treatment outcomes of the patients.
关键词
食管癌/放疗/替吉奥/急性骨髓抑制/危险因素Key words
Esophageal cancer/Radiotherapy/Tegio/Acute myelosuppression/Risk factor引用本文复制引用
出版年
2024
NETL
NSTL
万方数据